Emerging Therapies and Changing Architecture of HIV Management
Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study.
Aboud M, et al. 9th International AIDS Society Conference. July 23-26, 2017; Paris, France. Abstract TUAB0105LB.
American Pharmacists Association, 2017.
Bar KJ, et al. N Engl J Med. 2016;375(21):2037-2050.
Centers for Disease Control and Prevention, 2017.
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1–infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, et al. Lancet HIV. 2017;4(9):e384-e392.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, et al. Lancet. 2017;390(10107):2063-2072.
Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.
Hill AM, et al. Curr Opin HIV AIDS. 2018;13(2):102-111.
The INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, et al. Lancet. 2018;391(10123):839-849.
Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1–infected participants: day 8 and week 24 primary efficacy and safety results (BRIGHTE Study, formerly 205888/AI438-047).
Kozal M, et al. 16th European AIDS Conference. October 25-27, 2017; Milan, Italy. Abstract PS8/5.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA, et al. Lancet. 2017;390(10101):1499-1510.
Mesplède T, Wainberg MA. Viruses. 2015;7(7):3703-3718.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, et al. Lancet HIV. 2018;5(5):e211-e220.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, et al. Lancet HIV. 2018;5(1):e23-e34.
The role of substance use and mental health problems in medication adherence among HIV-infected MSM.
White JM, et al. LGBT Health. 2014;1(4):319-322.
White K, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI), 2018. March 4−7, 2018; Boston, MA. Abstract 532.
Review of Novel Agents and Approaches
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science